[Pneumococcal vaccination for children and adults]

Area of Science:

• Bacteriology
• Immunology
• Vaccinology

Background:

• Pneumococci are a primary cause of bacterial respiratory tract infections, bacteremia, and meningitis.
• Pneumococcal conjugate vaccines (PCV) are established as safe and effective for young children.
• PCV introduction has led to decreased rates of invasive pneumococcal disease (IPD), pneumonia, otitis media, and antibiotic-resistant infections.

Purpose of the Study:

• To summarize the impact of pneumococcal conjugate vaccines (PCV) on disease burden.
• To highlight the herd protection effect of PCV in unvaccinated populations.
• To present evidence for the efficacy and safety of the 13-valent PCV13 in adults.

Main Methods:

• Review of epidemiological data on pneumococcal disease trends.
• Analysis of vaccine efficacy and safety studies in pediatric and adult populations.
• Assessment of nasopharyngeal carriage and transmission dynamics post-PCV introduction.

Main Results:

• Significant reductions in IPD, pneumonia, otitis media, and antibiotic-resistant pneumococcal infections observed following PCV implementation in children.
• Demonstrated reduction in pneumococcal carriage and transmission, leading to herd protection.
• Evidence supporting the effectiveness and safety of 13-valent PCV13 in adults, irrespective of age.

Conclusions:

• PCV are crucial tools for controlling pneumococcal diseases in both vaccinated and unvaccinated populations.
• Herd immunity conferred by childhood PCV programs provides substantial protection to non-vaccinated groups, notably the elderly.
• The 13-valent PCV13 is recommended for all individuals with risk factors, underscoring its broad applicability and public health importance.